William L. Macias sold $57k of IMVT
Chief Medical Officer at Immunovant, Inc.. 2,383 shares at an average of $23.83, traded Jan 15, 2025, filed Jan 17, 2025.
Score components
- +15RoleOfficer
- +7Trade size$57k at market
- 0Share of holdings soldSold 0.7% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.8%, 3m -36.5%, 6m -24.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001764013-25-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | SOpen-market sale Common Stock | -1,883 | $23.81 | $45k | 359,908 | Jan 17, 2025 |
| Jan 15, 2025 | SOpen-market sale Common Stock | -94 | $24.19 | $2,274 | 359,814 | Jan 17, 2025 |
| Jan 15, 2025 | SOpen-market sale Common Stock | -387 | $23.81 | $9,214 | 359,427 | Jan 17, 2025 |
| Jan 15, 2025 | SOpen-market sale Common Stock | -19 | $24.19 | $460 | 359,408 | Jan 17, 2025 |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| Pro nowfree Oct 16, 2026 | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 0Weak | Immunovant, Inc. | Atul Pande director | $65k 1,500 shares | -1% | |
| 39Weak | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $135k 3,056 shares | -1% | |
| 50Moderate | Immunovant, Inc. | Tiago Girao Chief Financial Officer | $263k 6,798 shares | -3% | |
| 2Weak | Immunovant, Inc. | Atul Pande director | $60k 1,500 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $111k 2,857 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.